• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • SOD1 Therapies & Trials
      • SPG302
      • T Regulatory Cell Therapies
      • Ulefnersen – Ionis Pharmaceuticals
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Global Research Ambassadors
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Advisory Councils/Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Global Research Ambassadors

2026 Global Research Ambassadors

The Global Research Ambassadors program is a virtual learning and engagement program for people impacted by ALS/MND worldwide who want to deepen their understanding of ALS/MND research, treatment development, and advocacy.

Using a blended learning model that combines self-directed online content with interactive live sessions, the program helps participants build the knowledge and confidence needed to engage more meaningfully in research and advocacy conversations within the global ALS/MND community.

The program is designed to improve health literacy, strengthen global connections, and ensure that lived experience remains part of the future of ALS/MND research.

2026 Program Details

Dates: September 28–30 & October 1–9, 2026
Format: Virtual (Zoom and online learning platform)
Session Timing: Session times will vary across time zones to support global participation and inclusivity. Sessions may be scheduled at different times throughout the day to accommodate participants from multiple regions. Recordings will also be available for those unable to attend live.
Language: English (translation captions may be offered depending on demand)

How to Apply

Applications are open June 3 to July 3.

You are encouraged to apply if you are:

  • Living with ALS/MND
  • A current or former caregiver
  • An ALS/MND gene carrier without a diagnosis
  • A family member
  • Another member of the ALS/MND community with a strong interest in research and advocacy

Each applicant must submit a separate application.

Why the Program Matters

The Global Research Ambassadors program supports people affected by ALS/MND in building a stronger understanding of:

  • ALS/MND research and treatment development
  • Clinical trials and the research landscape
  • Scientific communication and health literacy
  • Research ethics and informed consent
  • Advocacy and lived experience engagement in research

The program uses a blended learning approach, combining online content, and interactive live sessions focused on discussion and practical application. 

What Participants Gain

Participants leave the program with:

  • A stronger understanding of ALS/MND and the global research landscape
  • Improved confidence discussing research and scientific developments
  • Practical tools for advocacy and community engagement
  • Connections with researchers, clinicians, and fellow participants worldwide
  • Recognition as a Global Research Ambassador

Participants who complete the program also receive:

  • A certificate of completion
  • Recognition through Alliance communications, including the website, newsletters, and social media
  • A Global Research Ambassador social media badge
  • Opportunities to join the Global ALS/MND Experience Network (GAMEN) for continued engagement and collaboration

One of the program’s greatest strengths is the global community it creates — connecting people affected by ALS/MND across countries, experiences, and perspectives.

Who Should Apply?

When people affected by ALS/MND are included in research conversations, it leads to stronger advocacy, better understanding of community priorities, and more meaningful research outcomes.

You may be a strong fit for the program if you:

  • Have a personal connection to ALS/MND
  • Want to better understand ALS/MND research and treatment development
  • Are interested in advocacy or research engagement
  • Are willing to actively participate in discussions and learning activities
  • Want to connect with others in the global ALS/MND community

To participate, you will need:

  • A device with internet access and a webcam
  • Time to attend most live sessions or watch recordings
  • A willingness to learn, engage, and contribute to discussion

If selected, participants are expected to review materials in advance, participate actively in sessions, and share what they learn with their communities following the program.

Primary Sidebar

  • Hanne Stenmose, Muskelsvindfonden, Denmark

    Hanne Stenmose, Muskelsvindfonden, Denmark

  • Bayley, Australia

    Bayley, Australia

  • Cath Muir

    Cath Muir
    Cath

  • Jette Odgaard Villemoes, Muskelsvindfonden, Denmark

    Jette Odgaard Villemoes, Muskelsvindfonden, Denmark

  • Fabio Carvalho

    Fabio Carvalho

  • Guoqiang Xu, Diagnosed 2016 , Shaanxi ALS Association, China

    Guoqiang Xu, Diagnosed 2016 , Shaanxi ALS Association, China

  • Valdomiro Xavier Honório, Brazil

    Valdomiro Xavier Honório, Brazil

  • Lombana, Spain

    Lombana, Spain

  • unnamed

    unnamed

  • Fabrice Kamp, Germany

    Fabrice Kamp, Germany

  • Inta Grubb, Diagnosed 2014,  MND Australia

    Inta Grubb, Diagnosed 2014, MND Australia

  • Kirsten Harley,  Diagnosed 2013,  Australia

    Kirsten Harley, Diagnosed 2013, Australia

  • Steven Spencer, Diagnosed 2014 , MND New Zealand

    Steven Spencer, Diagnosed 2014 , MND New Zealand

  • 83

    83

  • Angela Jansen, Deutsche Gesellschaft für Muskelkranke e.V.-DGM, Diagnosed 1995, Germany

    Angela Jansen, Deutsche Gesellschaft für Muskelkranke e.V.-DGM, Diagnosed 1995, Germany

  • Juvenal Bayona Romero

    Juvenal Bayona Romero

  • Irene McCaughey, Diagnosed 2011,  MND Australia

    Irene McCaughey, Diagnosed 2011, MND Australia

  • Emilienne Verhaegen, ALS Liga Belgium, Diagnosed 2014

    Emilienne Verhaegen, ALS Liga Belgium, Diagnosed 2014

  • Laurie Petit-Jean, Diagnosed 2012 , ARSLA, France

    Laurie Petit-Jean, Diagnosed 2012 , ARSLA, France

  • Anthony (Tony) Lynch, MND New South Wales, Diagnosed 2016, Australia

    Anthony (Tony) Lynch, MND New South Wales, Diagnosed 2016, Australia

  • Paul Launer, USA

    Paul Launer, USA

  • Horacio Fritzer, Argentina

    Horacio Fritzer, Argentina

  • Jose Rivero Muñoz, Diagnosed 2015, FYADENMAC, Mexico

    Jose Rivero Muñoz, Diagnosed 2015, FYADENMAC, Mexico

  • David Watson,  MND Scotland,  Diagnosed 2018

    David Watson, MND Scotland, Diagnosed 2018

  • Ali Var, Turkey

    Ali Var, Turkey

  • Chih Ching Darren Wong, MND Malaysia

    Chih Ching Darren Wong, MND Malaysia

  • Shera Mukherjee, Diagnosed 2013,  Asha Ek Hope Foundation, India

    Shera Mukherjee, Diagnosed 2013, Asha Ek Hope Foundation, India

  • Shay Rishoni, Diagnosed 2011 - Prize4Life, Israel

    Shay Rishoni, Diagnosed 2011 – Prize4Life, Israel

  • Enzo Maccarrone, AISLA ONLUS, Italy

    Enzo Maccarrone, AISLA ONLUS, Italy

  • Ian Roberts

    Ian Roberts

  • Animesh Kumar, Diagnosed 2013 , Asha Ek Hope Foundation, India

    Animesh Kumar, Diagnosed 2013 , Asha Ek Hope Foundation, India

  • Orlando Ruiz, Diagnosed 2001,  ACELA, Colombia

    Orlando Ruiz, Diagnosed 2001, ACELA, Colombia

  • Timmy, ALS Liga

    Timmy, ALS Liga

  • John Dinon, MND Australia

    John Dinon, MND Australia

  • Ian and Teresa Roberts

    Ian and Teresa Roberts

  • Tammy Moore and Eddy Lefrancois

    Tammy Moore and Eddy Lefrancois

  • Natalya Rybakova, Russian Charity ALS Foundation

    Natalya Rybakova, Russian Charity ALS Foundation

  • Hans Dieter Olszewski, Diagnosed 2010 , DGM, Germany

    Hans Dieter Olszewski, Diagnosed 2010 , DGM, Germany

  • Michael Lee, Australia

    Michael Lee, Australia

  • Joanne Pratt, Diagnosed 2011 , MND Australia

    Joanne Pratt, Diagnosed 2011 , MND Australia

  • Carlos Gomez Matallanas, Diagnosed 2014 , FUNDELA, Spain

    Carlos Gomez Matallanas, Diagnosed 2014 , FUNDELA, Spain

  • Kirsty Gerlach, MND New Zealand, Diagnosed 2017

    Kirsty Gerlach, MND New Zealand, Diagnosed 2017

  • Joy Blakeley, Diagnosed 2017 , MND Australia

    Joy Blakeley, Diagnosed 2017 , MND Australia

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Rolf Mauch, Association ALS Switzerland, Diagnosed 2015

    Rolf Mauch, Association ALS Switzerland, Diagnosed 2015

  • Diana Fernandez, Diagnosed 2009 , Asociación ELA Argentina

    Diana Fernandez, Diagnosed 2009 , Asociación ELA Argentina

  • Mike Rannie,  ALS Canada,  Diagnosed 2017

    Mike Rannie, ALS Canada, Diagnosed 2017

  • Jorge Melo, ABrELA, Brazil

    Jorge Melo, ABrELA, Brazil

  • Marcel R. Wernard, Diagnosed 2016,  ALS Patients Connected,  The Netherlands

    Marcel R. Wernard, Diagnosed 2016, ALS Patients Connected, The Netherlands

  • Danny Reviers, Diagnosed 1979 , ALS Liga België, Belgium

    Danny Reviers, Diagnosed 1979 , ALS Liga België, Belgium

Learn more about the March of Faces

Latest Tweets

  • Just now

Footer

Subscribe to our Bi-Monthly Newsletter

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login